HemoShear Therapeutics
HemoShear Therapeutics is a company focused on developing novel treatments for rare diseases, leveraging their REVEAL-Tx™ drug discovery platform and extensive network for obtaining human tissue samples.
Services
HemoShear Therapeutics develops novel treatments for patients with rare diseases such as cholestasis disorders and hepatitis D. The company leverages its REVEAL-Tx™ drug discovery platform, which combines biological and computational human disease models, to identify therapeutic targets. Additionally, HemoShear has developed translational models of human diseases by applying principles of physiological blood flow to human tissue.
Products
HemoShear Therapeutics has several key products under development. These include HST28468, which is being studied for cholestasis disorders and hepatitis D, and the small molecule HST5040 for the treatment of propionic acidemia and methylmalonic acidemia. They have also developed an in vitro liver model for nonalcoholic steatohepatitis (NASH) and a tumor microenvironment system (TMES) for modeling patient tumor biology and drug response.
Collaborations
HemoShear Therapeutics has collaborated with major pharmaceutical companies like Takeda Pharmaceutical Company and Horizon Therapeutics. These collaborations have aimed to identify and validate novel drug targets for conditions like NASH and gout. The company completed a four-year exclusive collaboration with Takeda, resulting in two novel drug targets for NASH, and is eligible to receive milestone payments of potentially $470 million plus royalties from the same. They are also eligible to receive more than $500 million plus royalties from Horizon Therapeutics.
Innovations in Drug Discovery
HemoShear Therapeutics has built an extensive network for obtaining explanted healthy and diseased tissue under IRB-approved protocols. This capability, combined with their computational techniques, allows the company to develop new human tissue-based models of diseases. Their innovations include a new human tissue-based model for rare liver diseases and the application of computational methods to identify novel therapeutic targets, exemplified by their in vitro liver model for NASH and the TMES for cancer research.
Location
HemoShear Therapeutics is located at 501 Locust Avenue, Suite 301, Charlottesville, Virginia 22902. This strategic location supports the company’s mission to develop groundbreaking medical treatments by providing access to essential resources and collaboration opportunities.